Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Freedom Finance and Binance Join Forces in Digital Assets 
HENDERSON, Nev., May 01, 2018 -- United Health Products, Inc. (UHP) (OTC:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is launching expanded and more robust animal testing for HemoStyp within the next two weeks. These tests are expected to take approximately two to three weeks to complete, following which the protocols for human pilot trials will be confirmed. The human pilot trials are expected to commence within three weeks of animal testing completion. Both the expanded animal testing and human trials are being conducted to support the company’s HemoStyp PMA submission for internal surgical use and are being done in coordination with the FDA.
“After consulting with the FDA regarding our PMA application for HemoStyp, we will conduct expanded animal testing, following which our human pilot trial protocol will be confirmed,” said Douglas K. Beplate, CEO, UHP. “We expect to complete both the expanded animal testing and human pilot trials within the next 14 weeks, following which we will present our findings to the FDA.”
About Premarket Approval (PMA): https://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/premarketapprovalpma/
About United Health Products, Inc.
United Health Products develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its products, and expanding its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact: 877-358-3444/ IR Contact: Philippe Niemetz, PAN Consultants Ltd. 212-344-6464
